Olivo Alicia C 4

Accession 0001077183-25-000043

CIK 0001077183other

View on SEC.gov Company Profile

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 4:41 PM ET

Size

31.1 KB

Accession

0001077183-25-000043

Insider Transaction Report

Form 4

Period: 2025-02-21

NEOGENOMICS INCNEO

Olivo Alicia C

EVP, GC & Business Development

Transactions

Award
Restricted Stock Unit
2025-02-21+63,238→ 63,238 total
Exercise: $0.00→ Common Stock (63,238 underlying)
Exercise/Conversion
Restricted Stock Unit
2025-02-23−8,443→ 16,886 total
Exercise: $0.00→ Common Stock (8,443 underlying)
Tax Payment
Common Stock
2025-02-23−2,504→ 45,353 total
Exercise/Conversion
Common Stock
2025-02-23+8,443→ 47,857 total
Award
Stock Option (Right to Buy)
2025-02-21+107,450→ 107,450 total
Exercise: $13.05Exp: 2035-02-21→ Common Stock (107,450 underlying)

Holdings

Stock Option (Right to Buy)
Exercise: $19.12Exp: 2026-09-30→ Common Stock (1,046 underlying)
1,046
Stock Option (Right to Buy)
Exercise: $10.05Exp: 2029-09-01→ Common Stock (55,332 underlying)
55,332
Stock Option (Right to Buy)
Exercise: $16.45Exp: 2034-02-23→ Common Stock (42,344 underlying)
42,344
Performance Stock Unit
Exercise: $0.00From: 2027-02-23→ Common Stock (25,330 underlying)
25,330
Stock Option (Right to Buy)
Exercise: $27.34Exp: 2027-05-01→ Common Stock (1,024 underlying)
1,024
Stock Option (Right to Buy)
Exercise: $48.99Exp: 2028-05-01→ Common Stock (516 underlying)
516
Stock Option (Right to Buy)
Exercise: $19.65Exp: 2030-05-11→ Common Stock (36,508 underlying)
36,508
Performance Stock Unit
Exercise: $0.00From: 2026-05-11→ Common Stock (19,508 underlying)
19,508
Restricted Stock Unit
Exercise: $0.00→ Common Stock (13,006 underlying)
13,006
Stock Option (Right to Buy)
Exercise: $46.10Exp: 2028-08-01→ Common Stock (1,117 underlying)
1,117
Stock Option (Right to Buy)
Exercise: $9.45Exp: 2029-05-01→ Common Stock (22,222 underlying)
22,222
Restricted Stock Unit
Exercise: $0.00From: 2026-01-13→ Common Stock (59,382 underlying)
59,382

Footnotes (18)

[F1]Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
[F10]On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F11]On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F12]On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F13]On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F14]On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.
[F15]On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to theperformance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stockover the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
[F16]On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
[F17]On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
[F18]On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant tothe performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company'scommon stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based onthe achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
[F2]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
[F3]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
[F4]On February 21, 2025, Ms. Olivo was granted 107,450 stock options. These options vest ratably over the first three anniversary dates of the grant date.
[F5]On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
[F6]Once vested, the shares of common stock are not subject to expiration.
[F7]On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
[F8]On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
[F9]On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.

Documents

1 file

4
wk-form4_1740519666.xmlPrimary
FORM 4

Issuer

NEOGENOMICS INC

CIK 0001077183

→

Entity typeother

Related Parties

filerCIK 0001951869

Filing Metadata

Form type: 4
Filed: Feb 24, 7:00 PM ET
Accepted: Feb 25, 4:41 PM ET
Size: 31.1 KB

View on SEC.gov